Trial Profile
A Phase 2 Study of MK-2206 in Patients With Relapsed or Refractory Diffuse Large-B Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Sep 2017
Price :
$35
*
At a glance
- Drugs MK 2206 (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 12 Apr 2017 New trial record